Physician, patient, and caregiver experience of different wet age-related macular degeneration anti-VEGF treatment regimens in Japan: a qualitative assessment

References

• FriedmanDSO’ColmainBJMunozBEye Diseases Prevalence Research GroupPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• KawasakiRYasudaMSongSJThe prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysisOphthalmology2010117592192720110127
   PubMed Web of Science ®Google Scholar
• SivaprasadSHykinPWhat is new in the management of wet age-related macular degeneration?Br Med Bull201310520121123393060
   PubMed Web of Science ®Google Scholar
• HatzKPrunteCTreat and extend versus pro re nata regimens of ranibizumab in neovascular age-related macular degeneration: a comparative 12 month studyActa Ophthalmol Epub2016324
   Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• FreundKBKorobelnikJFDevenyiRTreat-and-extend regimens with anti-VEGF agents in retinal diseases: a literature review and consensus recommendationsRetina20153581489150626076215
   PubMed Web of Science ®Google Scholar
• GuptaOPShienbaumGPatelAHFecarottaCKaiserRSRegilloCDA treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impactOphthalmology2010117112134214020591490
   PubMed Web of Science ®Google Scholar
• ArnoldJJCampainABarthelmesDTwo-year outcomes of “treat and extend” intravitreal therapy for neovascular age-related macular degenerationOphthalmology201512261212121925846847
   PubMed Web of Science ®Google Scholar
• HomerNGrewalDSMirzaRGLyonATGillMKTransitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month resultsEye (Lond)20152991152115526021870
   PubMed Web of Science ®Google Scholar
• RayessNHoustonSK3rdGuptaOPHoACRegilloCDTreatment outcomes after 3 years in neovascular age-related macular degeneration using a treat-and-extend regimenAm J Ophthalmol201515913825217859
   PubMed Web of Science ®Google Scholar
• RofaghaSBhisitkulRBBoyerDSSaddaSRZhangKSeven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP)Ophthalmology2013120112292229923642856
   PubMed Web of Science ®Google Scholar
• Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupMaguireMGMartinDFYingGSFive-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trialsOphthalmology201612381751176127156698
   PubMed Web of Science ®Google Scholar
• AmoakuWBlakeneySFreemanMAction on AMD GroupAction on AMD. Optimising patient management: act now to ensure current and continual delivery of best possible patient careEye (Lond)201226suppl 1S2S2122302094
   PubMed Web of Science ®Google Scholar
• Casaroli-MaranoRRouraMGrupo de Estudio OptimalDisponibilidad de recursos para pacientes con degeneración macular asociada a la edad de tipo húmedo. Estudio Optimal [Availability of resources for patients with wet age-related macular degeneration. Optimal study]Arch Soc Esp Oftalmol201388830731223886362
   PubMedGoogle Scholar
• MichelottiMMAbugreenSKellySPTransformational change: nurses substituting for ophthalmologists for intravitreal injections – a quality-improvement reportClin Ophthalmol2014875576124790403
   PubMedGoogle Scholar
• PrennerJLHalperinLSRycroftCHogueSWilliamsLZSeibertRDisease burden in the treatment of age-related macular degeneration: findings from a time-and-motion studyAm J Ophthalmol2015160472573126142721
   PubMed Web of Science ®Google Scholar
• DroegeKMMuetherPSHermannMMAdherence to ranibizumab treatment for neovascular age-related macular degeneration in real lifeGraefes Arch Clin Exp Ophthalmol201325151281128423086225
   PubMed Web of Science ®Google Scholar
• GohilRCrosby-NwaobiRForbesABurtonBHykinPSivaprasadSCaregiver burden in patients receiving ranibizumab therapy for neovascular age related macular degenerationPLoS One2015106e012936126056840
   PubMed Web of Science ®Google Scholar
• IidaTNarimatsuAAdachiKWangECYAnti-vascular endothelial growth factor outpatient treatment patterns in patients with exudative age-related macular degeneration from a Japanese hospital claims databaseJHEOR2014214152
   Google Scholar
• TakahashiHOhkuboYSatoARelationship between visual prognosis and delay of intravitreal injection of ranibizumab when treating age-related macular degenerationRetina20153571331133825719984
   PubMed Web of Science ®Google Scholar
• KashiwagiKより質の高い緑内障診療を目指して [Toward a high quality glaucoma care]Nippon Ganka Gakkai Zasshi2012116326929622568104
   PubMedGoogle Scholar
• MiyamuraYSotozonoCHigashiharaHHoshiSKinoshitaS認知症を伴う高齢者の重症眼感染症 [Severe ocular infection in elderly patients with dementia: a case study]Nippon Ganka Gakkai Zasshi20151191286386726817134
   PubMedGoogle Scholar
• SutoSHiraokaTOkamotoYOkamotoFOshikaTスマートフ ォンによる前眼部および眼底撮影 [Photography of anterior eye segment and fundus with smartphone]Nippon Ganka Gakkai Zasshi2014118171424505930
   PubMedGoogle Scholar